The Medicines Company

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Its mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. 
The Medicines Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Its pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.


Company Growth (employees)
Type
Public
HQ
Parsippany Troy Hills, US
Founded
1996
Size (employees)
410 (est)
The Medicines Company was founded in 1996 and is headquartered in Parsippany-Troy Hills, US

The Medicines Company Office Locations

The Medicines Company has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
8 Sylvan Way

The Medicines Company Financials and Metrics

The Medicines Company Financials

The Medicines Company's revenue was reported to be $167.8 m in FY, 2016
USD

Revenue (Q2, 2017)

18.7 m

Net income (Q2, 2017)

(397.3 m)

EBIT (Q2, 2017)

(409.3 m)

Market capitalization (13-Nov-2017)

2.3 b

Cash (30-Jun-2017)

202.4 m
The Medicines Company's current market capitalization is $2.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

5.1 m1.3 m309 m167.8 m

Revenue growth, %

(75%)23670%(46%)

R&D expense

139.3 m

General and administrative expense

319.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

90.5 m72.7 m50.3 m54.7 m37.6 m24.2 m18.7 m

Cost of goods sold

37 m18.8 m15.2 m

Gross profit

53.5 m31.5 m39.5 m

Gross profit Margin, %

59%63%72%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

376.7 m370.7 m373.2 m541.8 m

Accounts Receivable

2 k14.7 m

Inventories

12.6 m16 m20 m70.9 m

Current Assets

591.4 m657 m832.9 m654 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

462.4 m378.4 m368.3 m356.2 m607.1 m462.7 m508.8 m430.2 m644.2 m600.4 m436.7 m202.4 m

Inventories

91.5 m86 m86.3 m75.2 m127.4 m127.8 m114.3 m68.5 m74.1 m70.7 m71.7 m71.4 m

Current Assets

683.7 m595.7 m603.1 m584.9 m881.7 m660.4 m687.3 m560.8 m789.3 m717.4 m546.3 m436 m

Goodwill

186.8 m257.8 m284.8 m285.3 m314.1 m313.5 m313.2 m289.4 m255.6 m255.6 m255.6 m255.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

15.3 m(32.3 m)(352.7 m)(119.2 m)

Depreciation and Amortization

32.2 m34.4 m34.8 m31 m

Accounts Receivable

(15 m)(55 m)103 m30.1 m

Inventories

39 k(3.6 m)(5.3 m)569 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

14.2 m(5 m)(10.2 m)(27 m)5 m(41.5 m)(146.7 m)(92.5 m)182.4 m(86.3 m)(102.7 m)

Depreciation and Amortization

20 m7.9 m17 m26 m7.6 m14.9 m24.2 m

Accounts Receivable

(17.8 m)(2.8 m)(18.4 m)(18 m)56 m103 m115.8 m

Inventories

(15.1 m)1.1 m1.1 m12.1 m(46 m)(54.6 m)(57.8 m)68.5 m74.1 m70.7 m
Y, 2017

Financial Leverage

8.1 x
Show all financial metrics

The Medicines Company Market Value History

The Medicines Company's Web-traffic and Trends

The Medicines Company Online and Social Media Presence

The Medicines Company Company Life and Culture

You may also be interested in